1. Characterizing the role of the CD58-CD2 axis in anti-cancer immunity Ho, Patricia 2024 Theses OncologyImmunologyCytologyCancer--ImmunotherapyT cells--Therapeutic useMelanoma--Treatment
2. Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy) Ascierto, Paolo A.; Puzanov, Igor; Agarwala, Sanjiv S.; Blank, Christian; Carvajal, Richard D.; Demaria, Sandra; Dummer, Reinhard; Ernstoff, Marc; Ferrone, Soldano; Fox, Bernard A.; Gajewski, Thomas F.; Garbe, Claus; Hwu, Patrick; Lo, Roger S.; Long, Georgina V.; Luke, Jason J.; Osman, Iman; Postow, Michael A.; Sullivan, Ryan J.; Taube, Janis M.; Trinchieri, Giorgio; Zarour, Hassane M.; Caracò, Corrado; Thurin, Magdalena 2020 Articles Melanoma--TreatmentSkin--CancerCancer--ImmunotherapyBiochemical markersMonoclonal antibodies--Therapeutic use
3. A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma Clark, Joseph I.; Singh, Jatinder; Ernstoff, Marc S.; Lao, Christopher D.; Flaherty, Lawrence E.; Logan, Theodore F.; Curti, Brendan; Agarwala, Sanjiv S.; Taback, Bret; Cranmer, Lee; Lutzky, Jose; Luna, Theresa L.; Aung, Sandra; Lawson, David H. 2018 Articles Cancer--ImmunotherapyInterleukin-2Melanoma--TreatmentEnzyme inhibitors
4. Complete intracranial response to talimogene laherparepvec (T-Vec), pembrolizumab and whole brain radiotherapy in a patient with melanoma brain metastases refractory to dual checkpoint-inhibition Blake, Zoë; Marks, Douglas K.; Gartrell, Robyn D.; Hart, Thomas; Horton, Patti; Cheng, Simon K.; Taback, Bret; Horst, Basil; Saenger, Yvonne M. 2018 Articles Cancer--ImmunotherapyMelanoma--TreatmentMetastasisCancer--Treatment--Research
5. Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden Morrison, Carl; Pabla, Sarabjot; Conroy, Jeffrey M.; Nesline, Mary K.; Glenn, Sean T.; Dressman, Devin; Papanicolau-Sengos, Antonios; Burgher, Blake; Andreas, Jonathan; Giamo, Vincent; Qin, Moachun; Wang, Yirong; Lenzo, Felicia L.; Omilian, Angela; Bshara, Wiam; Zibelman, Matthew; Ghatalia, Pooja; Dragnev, Konstantin; Shirai, Keisuke; Madden, Katherine G.; Tafe, Laura J.; Shah, Neel; Kasuganti, Deepa; de la Cruz-Merino, Luis; Araujo, Isabel; Saenger, Yvonne M.; Bogardus, Margaret; Villalona-Calero, Miguel; Diaz, Zuanel; Day, Roger; Eisenberg, Marcia; Anderson, Steven M.; Puzanov, Igor; Galluzzi, Lorenzo; Gardner, Mark; Ernstoff, Marc S. 2018 Articles Melanoma--TreatmentCancer--ImmunotherapyBiochemical markersMedicine
6. Clinical benefit of high dose IL-2 (HD IL-2) therapy: evidence for improved overall survival in patients with stable disease Hughes, Tasha; Iodice, Gail M.; Basu, Sanjib; Bines, Steven; Kaufman, Howard 2013 Presentations (Communicative Events) Cancer--ImmunotherapyMelanoma--TreatmentRenal cell carcinomaInterleukin-2ImmunotherapyOncologyMedicineImmunology